For GHK-Cu wound healing, this means explicitly communicating: GHK-Cu is not FDA-approved as a drug for any indication Human wound-healing evidence is limited to small, non-randomized studies The compounding pharmacy source is not subject to the same oversight as FDA-approved manufacturers Alternative, evidence-based wound-healing options exist (negative pressure wound therapy, growth factor therapies like becaplermin, advanced wound dressings) Monitoring will be required, with associated lab costs Document this conversation in the medical record
INFORMATION What is GLOW GHK-CU (50mg) / BPC-157 (10mg) / TB500 (10mg)
A 2017 study found that GHK-Cu reduced androgen receptor gene expression, suggesting a complementary mechanism to direct DHT blockade
This product is not intended for personal use, medical use, cosmetic use, dietary use, supplementation, injection or human consumption